Delivery Order SPE2DB25D3005-SPE2DB25FQBQF

Award Date 1/13/25
Potential Completion Date 1/14/25
Potential Value $18K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,178.62 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of November 1, 2023 and was awarded on October 31, 2022. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,151.80 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has an ultimate completion date of January 9, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,298.86 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product, with a period of performance through January 29, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $62,693.66, is a Firm Fixed Price Delivery Order for the provision of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has a completion date of June 13, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,993.36 firm fixed-price delivery order contract is for the supply of GEMTESA 75 MG TABLET 90S, a pharmaceutical product. The contract has an ultimate completion date of February 19, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide GEMTESA 75 MG TABLET 90S. The $27,355.30 firm-fixed-price delivery order has an ultimate completion date of September 19, 2024. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,334.49 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 30S, a pharmaceutical product. The contract has an ultimate completion date of November 18, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of GEMTESA 75 MG TABLET 90S. The $18,838.92 firm fixed-price delivery order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of GEMTESA 75 MG TABLET 90S. The $1,340.85 firm fixed-price delivery order is a part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical for providing a comprehensive range of pharmaceutical products and medical supplies...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,945.39 firm fixed-price delivery order is for the supply of GEMTESA 75 MG TABLET 30S, a medical product, with a completion date of January 18, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, serving as a primary vehicle for providing a comprehensive...
  • SPE2DB25D3005
    Indefinite Delivery Contract
  • SPE2DB25D3005-SPE2DB25FQBQF
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of GEMTESA 75 MG TABLET 90S. The firm-fixed-price delivery order, valued at $17,602.32, has a completion date of January 14, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This contract award was not designated with a set-aside requirement.

Generated 5/21/25, 10:36 AM